N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 1.752 NOK -1.57% Market Closed
Market Cap: 572.1m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NYKD stock under the Base Case scenario is 4.026 NOK. Compared to the current market price of 1.752 NOK, Nykode Therapeutics ASA is Undervalued by 56%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NYKD Relative Value
Base Case
4.026 NOK
Undervaluation 56%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

7.2
P/S
P/S
Price to Sales
7.2
vs History
75
vs Industry
32
Median 3Y
22.9
Median 5Y
18.5
Industry
7.7
Forward
1 122.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-7.6
Industry
24.4
Forward
-17.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-1
Industry
21.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-1.1
Industry
22.9
More Details
0.4
P/B
P/B
Price to Book Value
0.4
vs History
85
vs Industry
70
Median 3Y
2.1
Median 5Y
3.2
Industry
3
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
25
Median 3Y
12.1
Median 5Y
8.3
Industry
8.2
Forward
-956.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
1.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
1.3
vs History
30
vs Industry
20
Median 3Y
-3.1
Median 5Y
-2.8
Industry
5.5
Forward
16.5
More Details
1.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
1.2
vs History
30
vs Industry
18
Median 3Y
-3
Median 5Y
-2.7
Industry
5.7
Forward
13.7
More Details
1
EV/OCF
EV/OCF
Enterprise Value to OCF
1
vs History
50
vs Industry
25
Median 3Y
-1.3
Median 5Y
1
Industry
6.2
More Details
1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
1
vs History
50
vs Industry
21
Median 3Y
-1.3
Median 5Y
1
Industry
4.3
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
27
Median 3Y
5.4
Median 5Y
24.9
Industry
5.3
More Details

Multiples Across Competitors

NYKD Competitors Multiples
Nykode Therapeutics ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Nykode Therapeutics ASA
OSE:NYKD
572.1m NOK 7.2 -2.2 1.3 1.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 159 077.2 -162 353 -197 148.4 -194 898.7
US
Abbvie Inc
NYSE:ABBV
370.1B USD 6.3 99.4 16.3 23.7
US
US BioTec Inc
OTC:USBC
156.3B USD 0 0 0 0
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.6 24 18.7 18.7
US
Gilead Sciences Inc
NASDAQ:GILD
144.2B USD 5 22.9 10.6 14.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 062.4 -526.3 -573.1 -557.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.9B USD 8.9 28 20.6 21.6
AU
CSL Ltd
ASX:CSL
108.4B AUD 4.5 23.2 15.3 19.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
63.6B USD 4.5 14.3 12.9 14.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
61.2B USD 24.9 -191.9 -480.3 -329.7
P/S Multiple
Revenue Growth P/S to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average P/S: 3 416 120.5
7.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 159 077.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5
4%
1.2
US
E
Epizyme Inc
F:EPE
2 062.4
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.9
10%
0.9
AU
CSL Ltd
ASX:CSL
4.5
8%
0.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.9
31%
0.8
P/E Multiple
Earnings Growth PEG
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average P/E: 35.3
Negative Multiple: -2.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 353 N/A N/A
US
Abbvie Inc
NYSE:ABBV
99.4
88%
1.1
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.3 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
N/A N/A
AU
CSL Ltd
ASX:CSL
23.2
15%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
7%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -191.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBITDA: 13.7
1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 148.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.7
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
15.3
12%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -480.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBIT: 16.2
1.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 898.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
28%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.7
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
17%
1.3
AU
CSL Ltd
ASX:CSL
19.1
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
10%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.7 N/A N/A

See Also

Summary
NYKD intrinsic value, competitors valuation, and company profile.
DCF Valuation
NYKD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NYKD stock valuation using valuation multiples.
Wall Street Estimates
NYKD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NYKD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 276,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.